Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B Virus Infection

Trial Profile

A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B Virus Infection

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 28 Nov 2018 Planned End Date changed from 27 Dec 2019 to 31 Jan 2019.
    • 28 Nov 2018 Planned primary completion date changed from 27 Dec 2019 to 31 Jan 2019.
    • 04 Mar 2017 This trial has been discontinued in Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top